Kymera Therapeutics, Inc. (KYMR) has a negative trailing P/E of -23.7, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. Trailing earnings yield is -4.23%.
Criteria proven by this page:
Overall SharesGrow Score: 45/100 with 1/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2018 | -69.0 | 0.00 | -43.01 | 0.00 | - |
| 2019 | -35.9 | -0.38 | -19.91 | 504.79 | - |
| 2020 | -60.6 | -9.39 | 9.73 | 81.17 | - |
| 2021 | -30.4 | -0.27 | 6.63 | 41.83 | - |
| 2022 | -8.7 | -0.23 | 2.75 | 28.75 | - |
| 2023 | -10.1 | 0.83 | 3.76 | 18.91 | - |
| 2024 | -13.5 | -0.74 | 3.61 | 64.14 | - |
| 2025 | -21.1 | -0.89 | 4.16 | 167.51 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2018 | $-0.48 | $0.00 | $-21.47M | - |
| 2019 | $-0.93 | $2.93M | $-41.29M | -1407.4% |
| 2020 | $-2.53 | $34.03M | $-43.95M | -129.1% |
| 2021 | $-2.04 | $72.83M | $-98M | -134.5% |
| 2022 | $-2.82 | $46.83M | $-151.83M | -324.2% |
| 2023 | $-2.52 | $78.59M | $-146.96M | -187% |
| 2024 | $-2.98 | $47.07M | $-223.86M | -475.6% |
| 2025 | $-3.69 | $39.2M | $-311.4M | -794.4% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-3.71 | $-4.26 – $-2.99 | $39.61M | $10.74M – $105.26M | 16 |
| 2027 | $-4.16 | $-5.77 – $-3.28 | $43.12M | $5.9M – $93.34M | 15 |
| 2028 | $-4.12 | $-5.04 – $-2.92 | $43.17M | $3.5M – $104.03M | 14 |
| 2029 | $-4.39 | $-12.42 – $0.85 | $54.14M | $4.39M – $130.46M | 8 |
| 2030 | $-3.32 | $-9.41 – $0.65 | $222.18M | $18.02M – $535.35M | 12 |
